Yamamura T, Kleiter I, Fujihara K, et al. – Via performing a phase 3, randomized, double-blind, placebo-controlled trial, researchers randomized individuals with neuromyelitis optica spectrum disorder (NMOSD) who were seropositive or seronegative for autoantibodies to anti–aquaporin-4 to receive either satralizumab (120 mg) or placebo (administered subcutaneously at weeks 0, 2, and 4 and every 4 weeks thereafter) added to stable immunosuppressant treatment to determine the effectiveness of satralizumab added to immunosuppressant treatment. A total of 83 individuals were recruited and assigned to the satralizumab group (n = 41) or the placebo group (n = 42). Satralizumab added to immunosuppressant treatment resulted in a lower risk of relapse compared with placebo in individuals with NMOSD; however, it did not vary from placebo in its impact on pain or fatigue.